Key Takeaways Ocugen's phase III liMeliGhT study of OCU400 in RP nears enrollment, with top-line data expected in Q4 2026.OCGN's OCU410ST for Stargardt disease is in phase II/III, with interim data expected in mid-2026.Ocugen expects phase II data for OCU410 in GA in Q1 2026, with phase III slated for mid-2026.Ocugen (OCGN) is making rapid progress in its gene therapy programs for retinal diseases, which have differentiated mechanisms of action. With all three key pipeline programs moving on schedule, Ocuge ...